These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38267821)

  • 1. Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.
    Sims EK; Cuthbertson D; Jacobsen L; Ismail HM; Nathan BM; Herold KC; Redondo MJ; Sosenko J
    J Clin Endocrinol Metab; 2024 Jul; 109(8):2116-2123. PubMed ID: 38267821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.
    Sims EK; Cuthbertson D; Herold KC; Sosenko JM
    Diabetes; 2021 Dec; 70(12):2922-2931. PubMed ID: 34551936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis.
    Kamrul-Hasan ABM; Mondal S; Nagendra L; Yadav A; Aalpona FTZ; Dutta D
    Endocr Pract; 2024 May; 30(5):431-440. PubMed ID: 38519028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
    Sims EK; Bundy BN; Stier K; Serti E; Lim N; Long SA; Geyer SM; Moran A; Greenbaum CJ; Evans-Molina C; Herold KC;
    Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
    Herold KC; Gitelman SE; Willi SM; Gottlieb PA; Waldron-Lynch F; Devine L; Sherr J; Rosenthal SM; Adi S; Jalaludin MY; Michels AW; Dziura J; Bluestone JA
    Diabetologia; 2013 Feb; 56(2):391-400. PubMed ID: 23086558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
    Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
    Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.
    Sims EK; Geyer SM; Long SA; Herold KC
    Diabetologia; 2023 Dec; 66(12):2283-2291. PubMed ID: 37667106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
    Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
    Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
    Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
    Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune therapy and β-cell death in type 1 diabetes.
    Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
    Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes.
    Baidal DA; Warnock M; Xu P; Geyer S; Marks JB; Moran A; Sosenko J; Evans-Molina C
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3273-e3280. PubMed ID: 35524749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials.
    Grando Alves G; Cunha L; Henkes Machado R; Lins de Menezes V
    Diabetes Obes Metab; 2024 Jul; 26(7):2652-2661. PubMed ID: 38602411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes.
    Simmons KM; Sosenko JM; Warnock M; Geyer S; Ismail HM; Elding Larsson H; Steck AK
    J Clin Endocrinol Metab; 2020 Nov; 105(11):e4094-101. PubMed ID: 32844178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
    Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
    N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials.
    Sosenko JM; Skyler JS; Herold KC; Schatz DA; Haller MJ; Pugliese A; Cleves M; Geyer S; Rafkin LE; Matheson D; Palmer JP;
    Diabetes; 2020 Aug; 69(8):1827-1832. PubMed ID: 32439823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
    Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
    Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.
    Mathieu C; Wiedeman A; Cerosaletti K; Long SA; Serti E; Cooney L; Vermeiren J; Caluwaerts S; Van Huynegem K; Steidler L; Blomme S; Rottiers P; Nepom GT; Herold KC;
    Diabetologia; 2024 Jan; 67(1):27-41. PubMed ID: 37782353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 diabetes prevention clinical trial simulator: Case reports of model-informed drug development tool.
    Morales JF; Klose M; Hoffert Y; Podichetty JT; Burton J; Schmidt S; Romero K; O'Doherty I; Martin F; Campbell-Thompson M; Haller MJ; Atkinson MA; Kim S
    CPT Pharmacometrics Syst Pharmacol; 2024 Aug; 13(8):1309-1316. PubMed ID: 38961520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of teplizumab for treatment of type 1 diabetes: A meta-analysis of randomized controlled trials.
    Heidari E; Shafiee A; Noorian S; Rafiei MA; Abbasi M; Amini MJ; Safari O; Aghamahdi F; Bakhtiyari M
    Diabetes Metab Res Rev; 2024 May; 40(4):e3806. PubMed ID: 38757421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of teplizumab in children and adolescents at risk of type 1 diabetes: perspectives of parents and caregivers from an Italian Pediatric Diabetes Center.
    Bombaci B; Passanisi S; Pecoraro M; Sorrenti L; Papa M; Salzano G; Lombardo F
    Acta Diabetol; 2024 May; 61(5):635-642. PubMed ID: 38381182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.